Pesquisa de referências

Will genetic test results be monetized in life insurance?

Recurso electrónico / Electronic resource
Registro MARC
Tag12Valor
LDR  00000cab a2200000 4500
001  MAP20210002335
003  MAP
005  20210126164036.0
008  210126e20201201usa|||p |0|||b|eng d
040  ‎$a‎MAP‎$b‎spa‎$d‎MAP
084  ‎$a‎341
24500‎$a‎Will genetic test results be monetized in life insurance?‎$c‎Oytun Haçarýz...[et al.]
520  ‎$a‎If life insurers are not permitted to use genetic test results in underwriting, they may face adverse selection. It is sometimes claimed that applicants will choose abnormally high sums insured as a form of financial gamble, possibly financed by life settlement companies (LSCs). The latter possibility is given some credence by the recent experience of stranger-originated life insurance (STOLI) in the United States. We examine these claims, and find them unconvincing for four reasons. First, apparently high mortality implies surprisingly high probabilities of surviving for decades, so the gamble faces long odds. Second, LSCs would have to adopt a different business model, involving much longer time horizons. Third, STOLI is being effectively dealt with by the U.S. courts. Fourth, the gamble would be predicated upon a deep understanding of the genetic epidemiology, which is evolving, subject to uncertain biases, and cannot predict the emergence of effective treatments.
650 4‎$0‎MAPA20090004726‎$a‎Tests genéticos
650 4‎$0‎MAPA20080570590‎$a‎Seguro de vida
650 4‎$0‎MAPA20080582661‎$a‎Selección adversa
650 4‎$0‎MAPA20080586294‎$a‎Mercado de seguros
7001 ‎$0‎MAPA20210001383‎$a‎Haçarýz, Oytun
7730 ‎$w‎MAP20077001748‎$t‎Risk management & insurance review‎$d‎Malden, MA : The American Risk and Insurance Association by Blackwell Publishing, 1999-‎$x‎1098-1616‎$g‎01/12/2020 Tomo 23 Número 4 - 2020 , p. 379-399